{"brief_title": "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen", "brief_summary": "This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.", "condition": "Breast Neoplasms", "intervention_type": "Drug", "intervention_name": "Celecoxib + Exemestane", "description": "Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.", "arm_group_label": "2.", "other_name": "Celebrex, Aromasin", "criteria": "Inclusion Criteria: - Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen. - Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen. - at least one measurable lesion Exclusion Criteria: - More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease. - Previous hormonotherapy for advanced disease other than Tamoxifen. - Myocardial infarction within previous 6 mo", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038103.xml"}